Connor Iapoce

Dr. Yeh discusses how Innovations in AI may improve access for patients in resource limited setting and improve detection of vision-threatening diseases.

The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.

A significant rate of reduction of geographic atrophy growth with pegcetacoplan was observed in both DERBY and OAKS over a 24-month period.

A look into major takeaways on efficacy, safety and functional data from the DERBY and OAKS trials on pegcetacoplan.

Brolucizumab was deemed superior to aflibercept in treatment naive patients with neovascular age-related macular degeneration.

Brolucizumab every four weeks met efficacy end points versus aflibercept at end of MERLIN study, but with higher incidences of intraocular inflammation.

GATHER2 reports a 14.3% reduction in mean rate of growth in GA area over 12 months with avacincaptad pegol compared to sham.

The least squares mean change from baseline in BCVA at Week 8 was 6.7 letters for SB15 versus 6.6 letters for aflibercept.

Key opinion leaders in the cardiometabolic space describe the importance of the introduction of SGLT2 inhibitors for heart failure treatment based on 2022 guidelines.

100 years after the discovery of insulin, the T1D Index may provide a foundational understanding of what steps need to be taken to both improve lives and reduce the incidence of T1D.

With the launch of the T1D index, the global burden of the disease and its impact is better understood. Dr. Kowalski joins to dig deeper into its importance and his personal connection to T1D.

PP-IRF through year 2 was independently associated with worse long-term visual acuity and scar development.

Patients with nAMD, DME, BRVO-ME, and CRVO-ME showed limited visual acuity outcomes in clinical practice.

The 0.002% eye drops were designated for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

The phase 2 Ladder trial indicated no evidence of worse macular atrophy with PDS compared with intravitreal ranibizumab 0.5-mg injections.

SGLT2 inhibitors, ARNIs, and MRAs were associated with a significant decrease in hospital admission for heart failure.

Diabetes mortality rates in 2017-2018 compared with 1999-2000 were highest and unchanged in rural counties.

The analysis suggests people with T2D newly receiving SGLT2 inhibitors may have lower risk for DED in comparison to those receiving GLP-1 RAs.

Trifocal IOLs were linked to greater improvement in visual acuity in uncorrected near visual acuity and enhanced uncorrected intermediate visual acuity.

Study data suggest the amount of damage to the corneal nerve fibers increased in line with the amount of impairment to glucose metabolism.

Microperimetry was safe and appeared predictive, detecting in at least 65% of cases the risk of AMD.

Brolucizumab use in treatment-naive and previously anti-VEGF-treated patients with nAMD was linked to improvements in visual acuity, CST, IRF and SRF.

Dr. Thosani discusses the convergence of technology and physiology, treatment advancements, and virtual medicine capabilities in the field of heart arrhythmia.

A reduction in aspirin use was associated with significantly less bleeding and health care use, without an increase in thrombotic outcomes.

Study data suggest HbA1c level from diabetes diagnosis is a strong biomarker for PDR and nephropathy, with the prevalence of both increasing more than 30 years after diagnosis.

Lifestyle interventions increased weight-specific quality of life in Latino youth with diabetes compared with usual care.

Children regularly engaged in physical activities had significantly better visual and stereoacuity than those who reported moderate, light or no activity.

People with diabetes in Italy and the UK reported the highest rates of anxiety at 63% and 51%, respectively.

Children identifying as Black, Mexican American, low-income, or non-US citizen were more likely to report poor subjective visual function from 2005 to 2008.

It is the first FDA-approved product indicated to improve kidney function in adults with HRS.